AbbVie and Nxera Pharma Enter $1.5 Billion Licensing Agreement for IBD Therapy
Nxera Pharma has entered into a significant licensing agreement with AbbVie to grant exclusive global rights for the development and commercialization of NXE0033744. This experimental therapy is designed to treat inflammatory bowel disease (IBD) by targeting the EP4 receptor. The deal is valued at up to $1.5 billion, providing Nxera Pharma with substantial potential milestone payments while expanding AbbVie's pipeline in the immunology space. The partnership aims to leverage AbbVie's global commercial infrastructure to bring this novel treatment to market.
Tickers: $ABBV
Topics: drug development licensing agreement pharmaceuticals